Roswell Park Comprehensive Cancer Center: Pediatric Multicenter Study Shows Targeted Therapy for High-Risk Hodgkin Lymphoma Reduces Relapse
November 03, 2022
November 03, 2022
BUFFALO, New York, Nov. 3 (TNSjou) -- The Roswell Park Comprehensive Cancer Center issued the following news release:
A targeted therapy for children with high-risk Hodgkin lymphoma (HL) was shown to significantly reduce relapse rates when tested in a large multicenter clinical trial conducted by the Children's Oncology Group (COG) and led by pediatric oncologists at Roswell Park Comprehensive Cancer Center, Children's Healthcare of Atlanta and Winship Cancer Institute of . . .
A targeted therapy for children with high-risk Hodgkin lymphoma (HL) was shown to significantly reduce relapse rates when tested in a large multicenter clinical trial conducted by the Children's Oncology Group (COG) and led by pediatric oncologists at Roswell Park Comprehensive Cancer Center, Children's Healthcare of Atlanta and Winship Cancer Institute of . . .